Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Free heme, specifically ferriprotoporphyrin IX (FP-IX), is a toxic byproduct generated during the intraerythrocytic stage of the Plasmodium falciparum life cycle (Hempelmann, 2007). As the parasite digests host hemoglobin to acquire essential amino acids, it releases large quantities of heme, which can cause oxidative damage to parasite membranes and enzymes (Egan, 2008). To mitigate this toxicity, the parasite converts free heme into an inert, crystalline form known as hemozoin (Hempelmann, 2007). This detoxification pathway is a critical vulnerability and serves as the primary target for several classes of antimalarial drugs (Egan, 2008). Quinolines, such as chloroquine, bind to free heme and prevent its sequestration into hemozoin, leading to the accumulation of toxic heme that kills the parasite (Egan, 2008). Additionally, artemisinin-based compounds are activated by heme-derived ferrous iron (Fe²⁺), which triggers the formation of lethal free radicals within the parasite (Klonis et al., 2011). Consequently, free heme and its iron derivatives are central to both the parasite's survival strategy and the efficacy of current frontline malaria treatments (Tilley et al., 2016).
Inhibition of heme biocrystallization into hemozoin (quinolines) and activation of endoperoxide drugs via reductive cleavage of the peroxide bridge by heme-derived Fe²⁺ (artemisinins) (Egan, 2008; Klonis et al., 2011).
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Free heme (ferriprotoporphyrin IX) and heme-derived ferrous iron (Fe²⁺) (FP-IX / Fe²⁺).